Clinical trials: Vaccine Prophylaxis
Liver Cirrhosis
Safety and Efficacy of a Non-replicating ChAdOx1 Vector Vaccine AZD1222 (COVISHIELD), for Prevention of COVID-19 in Patients With Liver Cirrhosis
COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), had caused widespread impact on health, including substantial mortality among those with pre-existing health conditions including…
- Trial name
- NCT04794946
- Testing
- Covishield
- Where
- India
- Volunteers
- 2,200 people, healthy volunteers welcome
- Sponsor
- Institute of Liver and Biliary Sciences, India
Prevention of Bacillus Anthracis (Anthrax) Infection
Phase II Study of Range and Schedule of rPA Doses
This is a dose ranging study comparing different vaccine schedules of rPA vaccine for anthrax. Safety and the capability to induce an immune response will be evaluated.
- Trial name
- NCT00170456
- Testing
- rPA vaccine containing alhydrogel
- Where
- 2 sites in United Kingdom
- Volunteers
- 415 people, healthy volunteers welcome
- Sponsor
- PharmAthene UK Limited
Typhoid Fever
Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects
The purpose of this trial is to examine the safety and immunogenicity of Ty800 oral vaccine in healthy adult subjects.
- Trial name
- NCT00498654
- Testing
- Ty800 (Salmonella typhi) Oral Vaccine
- Where
- 5 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Avant Immunotherapeutics
Infections, Papillomavirus
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18
Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the…
- Trial name
- NCT00122681
- Testing
- Cervarix™, Havrix™-based investigational formulation
- Where
- 138 sites in United States, Australia and 12 more
- Volunteers
- 18,729 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prevention of Zika Infection, Zika-Specific Immune Response
VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults
Background: People get Zika virus from infected mosquitos. They usually don t get very sick. But birth defects were reported in babies born to mothers who had Zika infection.
- Trial name
- NCT02996461
- Testing
- VRC-ZKADNA090-00-VP
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis
Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
This study will evaluate the immunogenicity, safety, and tolerability of rF1V-1018 vaccine
- Trial name
- NCT07207408
- Testing
- rF1V-1018
- Where
- 4 sites in United States
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
Vaccine-Preventable Diseases, Herpes Zoster
Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above
The purpose of this study is to evaluate the safety and immunogenicity of the investigational medicinal product, CVI-VZV-001.
- Trial name
- NCT06137755
- Testing
- CVI-VZV-001, Shingrix
- Where
- 2 sites in South Korea
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Aribio Lab Co., Ltd.
Healthy Volunteers
A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults
The main purposes of this study are to assess the safety, reactogenicity and immunogenicity of 4 dose levels of the bivalent combination Respiratory Syncytial Virus (RSV) / human Metapneumovirus (hMPV) vaccine candidate VXB-241…
- Trial name
- NCT06556147
- Testing
- VXB-241 60 mcg (Low Dose), VXB-241 120 mcg (Medium Dose), VXB-241 240 mcg (Medium-high Dose)
- Where
- 4 sites in Australia
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Sanofi
Autoimmune Rheumatologic Disease
Immunogenicity and Safety of MenB Vaccine in Pediatric Patients With Autoimmune Rheumatic Diseases
The goal of this clinical trial is to evaluate the humoral immunogenicity of the meningococcal B vaccine (MenB-4C) in pediatric patients with autoimmune rheumatic diseases (ARDs), compared to age- and sex-matched…
- Trial name
- MENB-PARD (NCT07252804)
- Testing
- Meningococcal B (Bexsero)
- Where
- 2 sites in Brazil
- Volunteers
- 263 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Rabies
Safety and Immunogenicity of ID vs IM Rabies Vaccine
Background: Burden: Rabies is a viral zoonotic disease that is 100% fatal if left untreated. Globally, Bangladesh is ranked third in terms of rabies infections.
- Trial name
- NCT07345208
- Testing
- Rabies vaccine
- Where
- Bangladesh
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Norovirus Prevention
Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults
The purpose of this study is to evaluate the safety of the norovirus bivalent virus-like particle (VLP) vaccine for further development by assessing the rates of serious adverse events (SAEs), unsolicited adverse events (AEs)…
- Trial name
- NCT02142504
- Testing
- Norovirus Bivalent VLP Vaccine
- Where
- 10 sites in United States
- Volunteers
- 454 people, healthy volunteers welcome
- Sponsor
- Takeda
HIV Infections
A Phase 1, Randomized, Blinded, Dose-escalation Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults.
The purpose of this study is to evaluate the safety, tolerability and immunogenicity of rAAV1-PG9DP when administered intramuscularly at different dose levels in healthy male adults.
- Trial name
- NCT01937455
- Testing
- rAAV1-PG9DP
- Where
- 2 sites in United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Rabies Human, Antibody
Prevention of Rabies With Four Doses of Rabies Vaccine
To evaluate the non inferiority of the immunogenicity of the test vaccine inoculated according to the four dose immunization program over the five dose immunization program and the batches consistency of immunogenicity according…
- Trial name
- NCT05545371
- Testing
- immunization procedures
- Where
- China
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- Changchun Zhuoyi Biological Co., Ltd
Ebola Vaccine
Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure
This study is a multi-center, open label, randomized phase 3b trial to assess the durability of Immunity induced by the Ebolavirus Vaccine VSV-EBOV ( with or without booster vaccination) in individuals at potential occupational…
- Trial name
- PREPARE (NCT05959421)
- Testing
- ERVEBO® (rVSV∆G-ZEBOV-GP)
- Where
- 2 sites in Germany
- Volunteers
- healthy volunteers welcome
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Tuberculosis Infection, Tuberculosis
BCG Revaccination in Children and Adolescents
Bacille Calmette Guerin (BCG) vaccine is one of the most used vaccines of the world, to reduce the risks of natural tuberculous infection.
- Trial name
- BRiC (NCT05330884)
- Testing
- BCG vaccine, Oral Chemoprophylaxis
- Where
- India
- Volunteers
- 9,200 people, healthy volunteers welcome
- Sponsor
- Tuberculosis Research Centre, India
Healthy Volunteers
Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV∆G-ZEBOV-GP Vaccine)
Background: The Ebola virus causes a severe disease that can be fatal. The usual incubation period to illness after being exposed is 2 to 21 days. There are only limited treatments currently available for Ebola infection.
- Trial name
- NCT02788227
- Testing
- rVSV∆G-ZEBOV-GP Vaccine (V920)
- Where
- 3 sites in United States, Canada
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Influenza
Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline (GSK) Biologicals' GSK1247446A Low Dose Influenza Vaccine Candidate
The purpose of this study is to evaluate the immunogenicity and the safety of candidate vaccines compared to Fluarix™ administered intramuscularly in subjects aged 18-59 years
- Trial name
- NCT00374842
- Testing
- Fluarix™, GSK1247446A
- Where
- Belgium
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine
This study is a randomized, placebo-controlled and open design, phase 4 clinical trial of an inactivated COVID-19 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.
- Trial name
- NCT04953325
- Testing
- Inactivated COVID-19 Vaccine, 23-valent pneumococcal polysaccharide vaccine, Inactivated Hepatitis A Vaccine
- Where
- China
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Prevention of Meningococcal Infection
Kinetics of B Cell Response in Infants Menjugate Vaccination
Kinetics of B cell response in infants Menjugate vaccination
- Trial name
- NCT00310700
- Testing
- Meningococcal C conjugate vaccine
- Where
- United Kingdom
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Novartis
Rabies Prevention
A Phase III Clinical Trial on Immunogenicity and Safety of Lyophilized Rabies Vaccine for Human Use (Human Diploid Cell)
Neutralizing antibody seroconversion rate and geometric mean concentration in seronegative participants of each group at 14 days after the first dose of immunization.
- Trial name
- NCT07500207
- Testing
- Experimental Lyophilized Human Rabies Vaccine (Human Diploid Cell), approved Rabies vaccine
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.